MedTrace Logo

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

NCT01276288 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2014-09-03

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to investigate the effect of BI 10773, hydrochlorothiazide and torasemide on changes in serum and urine electrolytes. Furthermore the pharmacodynamic and pharmacokinetic interactions between BI 10773 and diuretics should be assessed.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

BI 10773

multiple oral doses

DRUG

hydrochlorothiazide

multiple oral doses

DRUG

torasemide

multiple oral doses

DRUG

BI 10773

multiple oral doses

DRUG

torasemide

multiple oral doses

DRUG

BI 10773

multiple oral doses

DRUG

hydrochlorothiazide

multiple oral doses

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276288 on ClinicalTrials.gov